Insa Joost
Overview
Explore the profile of Insa Joost including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madlener M, Joost I
Inn Med (Heidelb)
. 2025 Jan;
66(2):190-198.
PMID: 39888404
Bacterial meningitis is a rare but severe disease with a high mortality. The most frequent pathogens in adults are pneumococcus, meningococcus and Listeria. The most important key symptoms are headache,...
2.
Simon M, Dreyer S, Joost I, Rubbert C, Schipper J, Kristin J
Eur Arch Otorhinolaryngol
. 2024 Nov;
PMID: 39613850
Introduction: Skull base osteomyelitis is a rare but potentially life-threatening disease. It usually occurs as a complication of severe otitis externa or infection in the nasopharynx, often in immunocompromised patients....
3.
Rieg S, Ernst A, Peyerl-Hoffmann G, Joost I, Camp J, Hellmich M, et al.
J Antimicrob Chemother
. 2020 May;
75(8):2282-2290.
PMID: 32355950
Objectives: To investigate whether Staphylococcus aureus bloodstream infection (SAB) patients at high risk for complications or relapse benefit from combination therapy with adjunctive rifampicin or fosfomycin. Methods: In this post...
4.
Mathe P, Joost I, Peyerl-Hoffmann G, Schneider C, Kern W, Rieg S
J Invest Dermatol
. 2020 Feb;
140(9):1870-1872.
PMID: 32081611
No abstract available.
5.
Kaasch A, Kern W, Joost I, Hellmich M, Seifert H, Rieg S
Open Forum Infect Dis
. 2019 May;
6(5):ofz170.
PMID: 31111077
Background: The standard treatment duration in low-risk bloodstream (SAB) is 14 days. However, it is unclear whether an extended course of antimicrobial therapy is necessary in patients with clinically uninfected...
6.
Joost I, Bothe W, Pausch C, Kaasch A, Lange B, Peyerl-Hoffmann G, et al.
J Infect
. 2018 May;
77(1):30-37.
PMID: 29778631
Objectives: Ventricular assist devices (VAD) are increasingly implanted in patients with terminal heart failure. Here we describe the clinical course, management and outcome of VAD patients with S. aureus bloodstream...
7.
Joost I, Kaasch A, Pausch C, Peyerl-Hoffmann G, Schneider C, Voll R, et al.
J Infect
. 2017 Mar;
74(6):575-584.
PMID: 28322887
Objectives: Patients with rheumatoid arthritis (RA) are considered to be at increased risk of severe infections. We here describe the clinical characteristics, course and outcome of RA patients with Staphylococcus...
8.
Joost I, Steinfurt J, Meyer P, Kern W, Rieg S
BMC Infect Dis
. 2016 Oct;
16(1):586.
PMID: 27765025
Background: Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter, prospective...
9.
Schmitt J, Joost I, Skaar E, Herrmann M, Bischoff M
Microbiology (Reading)
. 2012 Aug;
158(Pt 10):2619-2631.
PMID: 22859613
Staphylococcus aureus is a major human pathogen and a common cause of nosocomial infections. This facultative pathogen produces a large arsenal of virulence factors, including the haemolysins, which allow the...
10.
Motloch L, Rottlaender D, Darabi T, Joost I, Erdmann E, Hoppe U
Tex Heart Inst J
. 2011 Apr;
38(2):197-200.
PMID: 21494537
Candida albicans infections after prosthetic graft implantation due to acute aortic dissection are rare. A combination of surgical resection and lifelong antifungal drug therapy is the gold standard for treatment...